Poor
Not Aligned
Patient Risk:
Moderate
Summary
Partially matches the label for indication, dosage form (chewable ferric-based binder), and mechanism-related points, but includes at least one clear contradiction to label-described active moiety/composition and multiple claims that are absent from the provided label sections (e.g., patient assistance, manufacturer, patent resources, alternative therapies, GI ion release).
Category Scores
Accurate Statements
Velphoro is used to treat hyperphosphatemia in adult patients with chronic kidney disease on dialysis.
Supported by 1 INDICATIONS AND USAGE (adults and pediatric patients 9 years of age and older with CKD on dialysis).
Velphoro is a chewable ferric-based phosphate binder.
Supported by 11 DESCRIPTION (chewable tablets; iron-containing iron(III) oxyhydroxide moiety).
Binding ferric phosphate reduces absorption of phosphate from the diet.
Supported by 12.1 Mechanism of Action (reduced dietary phosphate absorption).
Unsupported Statements
Velphoro may have manufacturer-sponsored patient assistance programs available to help eligible individuals manage the cost of treatment.
Absent from the provided FDA label sections.
Patient assistance programs are designed to reduce out-of-pocket expenses for those who meet specific financial and medical criteria.
Absent from the provided FDA label sections.
Velphoro is manufactured by Fresenius Medical Care.
Absent from the provided FDA label sections.
Velphoro patent expiry information can be found on pharmaceutical patent tracking resources.
Absent from the provided FDA label sections.
Alternative treatments for hyperphosphatemia in dialysis patients include other phosphate binders such as calcium-based binders, sevelamer carbonate, and lanthanum carbonate.
Absent from the provided FDA label sections.
Commonly reported side effects of Velphoro include diarrhea.
6 ADVERSE REACTIONS is cited in the provided evaluation set, but the specific adverse reaction content (including whether 'diarrhea' is 'commonly reported') is not included in the label text provided. Cannot be verified against supplied label excerpts.
Commonly reported side effects of Velphoro include nausea.
6 ADVERSE REACTIONS is cited in the provided evaluation set, but the specific adverse reaction content (including whether 'nausea' is 'commonly reported') is not included in the label text provided. Cannot be verified against supplied label excerpts.
Commonly reported side effects of Velphoro include vomiting.
6 ADVERSE REACTIONS is cited in the provided evaluation set, but the specific adverse reaction content (including whether 'vomiting' is 'commonly reported') is not included in the label text provided. Cannot be verified against supplied label excerpts.
Commonly reported side effects of Velphoro include constipation.
6 ADVERSE REACTIONS is cited in the provided evaluation set, but the specific adverse reaction content (including whether 'constipation' is 'commonly reported') is not included in the label text provided. Cannot be verified against supplied label excerpts.
Commonly reported side effects of Velphoro include abdominal pain.
6 ADVERSE REACTIONS is cited in the provided evaluation set, but the specific adverse reaction content (including whether 'abdominal pain' is 'commonly reported') is not included in the label text provided. Cannot be verified against supplied label excerpts.
In the gastrointestinal tract, Velphoro releases iron and chloride ions.
Not supported by the provided label excerpts (12.1 describes ligand exchange binding/elimination with feces, not release of chloride ions).
Contradictions
High
AI Statement
Velphoro’s active ingredient is ferric trichloride hexahydrate.
Label Reference
11 DESCRIPTION (drug substance mixture of polynuclear iron(III)-oxyhydroxide, sucrose, and starches; active moiety is polynuclear iron(III)-oxyhydroxide; practically insoluble and cannot be absorbed).
Important Omissions
Pediatric indication detail (label includes pediatric patients 9 years of age and older in addition to adults).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Primary risk arises from a direct label contradiction regarding active ingredient identity. Additional absent/uncertain safety-related details (e.g., side effects 'commonly reported') cannot be confirmed from the supplied adverse reaction text excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Contains a clear contradiction to the label regarding the active ingredient/composition (claims ferric trichloride hexahydrate as the active ingredient, while the label describes polynuclear iron(III)-oxyhydroxide as the active moiety within a sucrose/starch mixture).
Suggested Improvement
Remove or correct the active ingredient claim to match 11 DESCRIPTION, and restrict other claims to information present in the provided label sections (avoid patient assistance/manufacturer/patent/alternative-therapy statements and unverified 'commonly reported' adverse reaction assertions).